Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
1. A binding molecule genetically engineered to specifically recognize and bind to an epitope in influenza hemagglutinin protein (HA), having neutralizing activity against influenza viruses comprising HA of the H3 subtype and having cross-neutralizing activity against at least an influenza virus comprising HA of the H7 subtype, and/or an influenza virus comprising HA of the H10 subtype, wherein the binding molecule is selected from the group consisting of:
a) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:81, a heavy chain CDR2 region of SEQ ID NO:82, a heavy chain CDR3 region of SEQ ID NO:83, a light chain CDR1 region of SEQ ID NO:84, a light chain CDR2 region of SEQ ID NO:85, and a light chain CDR3 region of SEQ ID NO:86,
b) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:87, a heavy chain CDR2 region of SEQ ID NO:88, a heavy chain CDR3 region of SEQ ID NO:89, a light chain CDR1 region of SEQ ID NO:90, a light chain CDR2 region of SEQ ID NO:91, and a light chain CDR3 region of SEQ ID NO:92,
c) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:103, a heavy chain CDR2 region of SEQ ID NO:104, a heavy chain CDR3 region of SEQ ID NO:105, a light chain CDR1 region of SEQ ID NO:106, a light chain CDR2 region of SEQ ID NO:107, and a light chain CDR3 region of SEQ ID NO:108,
d) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:109, a heavy chain CDR2 region of SEQ ID NO:110, a heavy chain CDR3 region of SEQ ID NO:111, a light chain CDR1 region of SEQ ID NO:112, a light chain CDR2 region of SEQ ID NO:113, and a light chain CDR3 region of SEQ ID NO:114,
e) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:115, a heavy chain CDR2 region of SEQ ID NO:116, a heavy chain CDR3 region of SEQ ID NO:117, a light chain CDR1 region of SEQ ID NO:118, a light chain CDR2 region of SEQ ID NO:119, and a light chain CDR3 region of SEQ ID NO:120,
f) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:121, a heavy chain CDR2 region of SEQ ID NO:122, a heavy chain CDR3 region of SEQ ID NO:123, a light chain CDR1 region of SEQ ID NO:124, a light chain CDR2 region of SEQ ID NO:125, and a light chain CDR3 region of SEQ ID NO:126,
g) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:126, a heavy chain CDR2 region of SEQ ID NO:127, a heavy chain CDR3 region of SEQ ID NO:128, a light chain CDR1 region of SEQ ID NO:129, a light chain CDR2 region of SEQ ID NO:130, and a light chain CDR3 region of SEQ ID NO:131,
h) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:132, a heavy chain CDR2 region of SEQ ID NO:133, a heavy chain CDR3 region of SEQ ID NO:134, a light chain CDR1 region of SEQ ID NO:135, a light chain CDR2 region of SEQ ID NO:136, and a light chain CDR3 region of SEQ ID NO:137,
i) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:138, a heavy chain CDR2 region of SEQ ID NO:139, a heavy chain CDR3 region of SEQ ID NO:140, a light chain CDR1 region of SEQ ID NO:141, a light chain CDR2 region of SEQ ID NO:142, and a light chain CDR3 region of SEQ ID NO:143, and
j) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:144, a heavy chain CDR2 region of SEQ ID NO:145, a heavy chain CDR3 region of SEQ ID NO:146, a light chain CDR1 region of SEQ ID NO:147, a light chain CDR2 region of SEQ ID NO:148, and a light chain CDR3 region of SEQ ID NO:149,
k) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:150, a heavy chain CDR2 region of SEQ ID NO:151, a heavy chain CDR3 region of SEQ ID NO:152, a light chain CDR1 region of SEQ ID NO:153, a light chain CDR2 region of SEQ ID NO:154, and a light chain CDR3 region of SEQ ID NO:155,
l) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:156, a heavy chain CDR2 region of SEQ ID NO:157, a heavy chain CDR3 region of SEQ ID NO:158, a light chain CDR1 region of SEQ ID NO:159, a light chain CDR2 region of SEQ ID NO:160, and a light chain CDR3 region of SEQ ID NO:161,
m) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:162, a heavy chain CDR2 region of SEQ ID NO:163, a heavy chain CDR3 region of SEQ ID NO:164, a light chain CDR1 region of SEQ ID NO:165, a light chain CDR2 region of SEQ ID NO:166, and a light chain CDR3 region of SEQ ID NO:167,
n) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:168, a heavy chain CDR2 region of SEQ ID NO:169, a heavy chain CDR3 region of SEQ ID NO:170, a light chain CDR1 region of SEQ ID NO:171, a light chain CDR2 region of SEQ ID NO:172, and a light chain CDR3 region of SEQ ID NO:173,
o) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:173, a heavy chain CDR2 region of SEQ ID NO:174, a heavy chain CDR3 region of SEQ ID NO:175, a light chain CDR1 region of SEQ ID NO:176, a light chain CDR2 region of SEQ ID NO:177, and a light chain CDR3 region of SEQ ID NO:178, and
p) a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:179, a heavy chain CDR2 region of SEQ ID NO:180, a heavy chain CDR3 region of SEQ ID NO:181, a light chain CDR1 region of SEQ ID NO:182, a light chain CDR2 region of SEQ ID NO:183, and a light chain CDR3 region of SEQ ID NO:184.
2. A binding molecule genetically engineered to specifically recognize and bind to an epitope in influenza hemagglutinin protein (HA), having neutralizing activity against influenza viruses comprising HA of the H3 subtype and having cross-neutralizing activity against at least an influenza virus comprising HA of the H7 subtype, and/or an influenza virus comprising HA of the H10 subtype, wherein the binding molecule is selected from the group consisting of:
a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:109, a heavy chain CDR2 region of SEQ ID NO:110, a heavy chain CDR3 region of SEQ ID NO:111, a light chain CDR1 region of SEQ ID NO:112, a light chain CDR2 region of SEQ ID NO:113, and a light chain CDR3 region of SEQ ID NO:114,
a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:138, a heavy chain CDR2 region of SEQ ID NO:139, a heavy chain CDR3 region of SEQ ID NO:140, a light chain CDR1 region of SEQ ID NO:141, a light chain CDR2 region of SEQ ID NO:142, and a light chain CDR3 region of SEQ ID NO:143, and
a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:144, a heavy chain CDR2 region of SEQ ID NO:145, a heavy chain CDR3 region of SEQ ID NO:146, a light chain CDR1 region of SEQ ID NO:147, a light chain CDR2 region of SEQ ID NO:148, and a light chain CDR3 region of SEQ ID NO:149.
3. A human monoclonal antibody specifically binding influenza HA protein, wherein the human monoclonal antibody comprises:
(a) a heavy chain CDR1 region of SEQ ID NO:109, a heavy chain CDR2 region of SEQ ID NO:110, a heavy chain CDR3 region of SEQ ID NO:111, a light chain CDR1 region of SEQ ID NO:112, a light chain CDR2 region of SEQ ID NO:113, and a light chain CDR3 region of SEQ ID NO:114, or
(b) a heavy chain CDR1 region of SEQ ID NO:144, a heavy chain CDR2 region of SEQ ID NO:145, a heavy chain CDR3 region of SEQ ID NO:146, a light chain CDR1 region of SEQ ID NO:147, a light chain CDR2 region of SEQ ID NO:148, and a light chain CDR3 region of SEQ ID NO:149.
4. The human monoclonal antibody of claim 3 , wherein the human monoclonal antibody comprises:
the heavy chain CDR1 region of SEQ ID NO:109,
the heavy chain CDR2 region of SEQ ID NO:110,
the heavy chain CDR3 region of SEQ ID NO:111,
the light chain CDR1 region of SEQ ID NO:112,
the light chain CDR2 region of SEQ ID NO:113, and
the light chain CDR3 region of SEQ ID NO:114.
5. The human monoclonal antibody of claim 3 , wherein the human monoclonal antibody comprises:
the heavy chain CDR1 region of SEQ ID NO:144,
the heavy chain CDR2 region of SEQ ID NO:145,
the heavy chain CDR3 region of SEQ ID NO:146,
the light chain CDR1 region of SEQ ID NO:147,
the light chain CDR2 region of SEQ ID NO:148, and
the light chain CDR3 region of SEQ ID NO:149.
6. A method of diagnosing influenza infection in a subject, the method comprising:
contacting the human monoclonal antibody of claim 3 with a biological sample of the subject in order to diagnose the influenza infection in the subject.
7. A method of treating or prophylaxing against influenza infection in a subject, the method comprising:
administering the human monoclonal antibody of claim 3 to the subject to treat or prophylax the subject against an influenza infection caused by influenza virus comprising HA of the H3 subtype.
8. An immunoconjugate comprising:
the human monoclonal antibody of claim 3 , and
at least one tag associated therewith.
9. A composition comprising:
the human monoclonal antibody of claim 3 , and
a pharmaceutically acceptable excipient.
10. A process for producing a human monoclonal antibody having neutralizing activity against influenza viruses comprising hemagglutinin protein (HA) of the H3 subtype and having cross-neutralizing activity against at least an influenza virus comprising HA of the H7 subtype, and/or an influenza virus comprising HA of the H10 subtype, wherein the process comprises:
culturing a host cell comprising a vector comprising a polynucleotide encoding the human monoclonal antibody of claim 3 under conditions conducive to the expression of the human monoclonal antibody, and, optionally,
recovering the expressed human monoclonal antibody.
11. The process of claim 10 , wherein the host cell is a human cell.